JGC
VRTX icon

J. Goldman & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

J. Goldman & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,700
Closed -$771K – 903
2025
Q4 		$771K Buy
+1,700
New +$733K 0.02% 419
2023
Q3 		– Sell
-17,500
Closed -$6.16M – 494
2023
Q2 		$6.16M Buy
+17,500
New +$5.9M 0.22% 111

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

J. Goldman & Co's VRTX Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 12,311 shares worth $6.12M. The stake represents 0.16% of the portfolio and ranks #176 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in VRTX as recently as Q2 2025.

J. Goldman & Co first reported a position in VRTX in Q2 2017 and has held it in 9 quarters since. The position peaked at $8.71M in Q4 2022. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • J. Goldman & Co held 12,311 shares of Vertex Pharmaceuticals worth $6.12M as of Q2 2026.
  • Vertex Pharmaceuticals was a new J. Goldman & Co position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.16% of J. Goldman & Co's portfolio in Q2 2026, its #176 holding.
  • J. Goldman & Co first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 9 quarters since.
  • J. Goldman & Co's Vertex Pharmaceuticals position peaked at $8.71M in Q4 2022.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.